J&J-Achillion partner to develop hep C drugs
Johnson & Johnson is expanding its reach in the lucrative hepatitis C drug market after announcing it will collaborate with Achillion Pharmaceuticals to develop its HCV drugs.
Johnson & Johnson is expanding its reach in the lucrative hepatitis C drug market after announcing it will collaborate with Achillion Pharmaceuticals to develop its HCV drugs.
Achillion will be entitled to receive an upfront payment of $225 million from J&J in exchange for granting the development and marketing rights for its experimental drugs aimed at treating hepatitis C, ACH-3102 and sovaprevir, currently in phase 2 stage of trials, as well as ACH-3422, which is in early stage trials.
Related: Hep C, cancer drugs make up bigger percentage of Rx costs
"A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV,” according to a J&J statement. "An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration.”
Achillion’s ACH-3102 holds strong potential to initiate a second wave of hepatitis C drugs by reducing the treatment time of liver disease to the minimum, according to Bidness.
“ACH-3102, in addition to its fast track designation granted by US FDA last week, has established a significant breakthrough reduction in HCV treatment duration, as well a strong efficacy rate. As per the interim results of a phase II study revealed in February this year, ACH-3102, when used in combination with Gilead's Sovaldi, proved to achieve a 100% cure rate,” the article stated.
Related: States blame hep C cases for increased opioid abuse
“In addition to the already achieved breakthrough success, Achillion is planning to reduce the HCV treatment time further to the unimaginable four weeks only; the company has various trials in process for its investigational HCV regimens to achieve this goal,” Bidness stated.
Read next: AbbVie hopes to advance HCV treatment for genotype 4
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
